Genmab — September 2018
-
20:25 i går. Jan siger at MAIA readout expected soon.
-
Angående 7:46 så er der jo lidt i linket: Preliminary evidence of efficacy (maximum change from baseline in sum of target lesion diameters) was observed in a patient with squamous cell carcinoma (-20%), a patient with wtEGFR adenocarcinoma (-20%), and 4 patients with EGFR-mutant adenocarcinoma (≥-30%).
-
@gentogen 9:06 - squamous cell carcinoma (SCC) er cancer i de øverste hudc
eller og er derfor ofte flade i struktur, så en 20% reduktion i diameter kan oversættes til =<35% reduktion i en 3 dimensionel tumor. Nye tilfælde (UV stråling/sol) i USA er 115 tilfælde/time!! -
Det Jan omtalte fra Journal of clinical oncology: "Conclusion:
Baseline corticosteroid use of ≥ 10 mg of prednisone equivalent was associated with poorer outcome in patients with non–small-cell lung cancer who were treated with PD-(L)1 blockade. Prudent use of corticosteroids at the time of initiating PD-(L)1 blockade is recommended." -
-
Winkel var inde på at isatuximab-folkene måske havde knækket koden i solide. I hvert fald fastholder de kombi-forsøget med Cemiplimab (PD-1 blokker) i prostata cancer og nsclc https://www.clinicaltrials.gov/ct2/show/NCT03367819?term=isatuximab+nsclc&rank=1
-
-
Her er det nye studie, som Winkel omtaler, med isa i diverse solide https://www.clinicaltrials.gov/ct2/show/NCT03637764?term=isatuximab&draw=2&rank=11
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind